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Chronic wounds represent a major healthcare and economic problem worldwide. Advanced 
wound dressings that incorporate bioactive compounds have great potential for improving 
outcomes in patients with chronic wounds but significant challenges in designing treatments that 
are effective in long-standing, non-healing wounds. Here, we developed an optimized wound 
healing gel that delivers syndecan-4 proteoliposomes (“syndesomes”) with FGF-2 to enhance 
diabetic wound healing. In vitro studies demonstrated that syndesomes markedly increased 
migration of keratinocytes and fibroblasts isolated from both non-diabetic and diabetic donors. In 
addition, syndesome treatment led to increased endocytic processing of FGF-2 that included 
enhanced recycling of FGF-2 to the cell surface after uptake.  The optimized syndesome 
formulation was incorporated into an alginate wound dressing and tested in a splinted wound 
model in diabetic, ob/ob mice. We found that wounds treated with syndesomes and FGF-2 had 
markedly enhanced wound closure in comparison to wounds treated with only FGF-2. Moreover, 
we show that syndesomes have an immunomodulatory effect on wound macrophages, leading to 
a shift towards the M2 macrophage phenotype and alterations in the wound cytokine profile. 
Together, these studies showed that delivery of exogenous syndecan-4 is an effective method for 
enhancing wound healing in the long-term diabetic diseased state.  
 
Keywords: wound healing, diabetic ulcers, syndecan-4, immunomodulation, fibroblast growth 
factor-2
Page 3 of 48 
  
INTRODUCTION 
Type 2 diabetes is a highly prevalent disorder that impacts 347 million people worldwide. 
Neuropathy and microvascular angiopathy are common complications of diabetes and contribute 
to a 12-25% lifetime risk of developing diabetic ulcers.[1] These diabetic ulcers are responsible 
for 25-50% of the total cost of diabetes treatment and are the most common cause of limb 
amputations in the United States.[2] Non-healing, diabetic ulcers are a complex clinical problem 
requiring a multifaceted treatment plan with standard therapeutic components including removal 
of necrotic tissue from wound (debridement), reduction of pressure in the wound (offloading), 
infection control, surgical revascularization, and limb elevation or compression. However, in 
many cases these treatments are ineffective, leaving patients with chronic ulcers and enhanced 
risk for limb amputation.  
 A number of advanced wound dressings have been used to enhance healing of chronic 
ulcers. The most prevalent approaches to bioactive dressings can be broadly classified into the 
categories of local delivery of growth factors,[3] delivery of therapeutic genes[4] or delivery of 
stem cells.[5] Of these strategies, only growth factors have been tested in large clinical trials, 
perhaps due to the safety and logistical challenges accompanying gene or stem cell therapies. 
However, the vast majority growth factor therapies have limited success in clinical trials for 
wound healing.[6] The only approved clinical growth factor treatment for chronic wounds is 
recombinant PDGF-BB (Becaplermin), and, while approved by the FDA, it has shown mixed 
results in clinical trials on chronic ulcers.[7] Other growth factors including FGF-2 and EGF have 
either shown no improvement or only moderate benefits in small clinical trials.[8] Thus, while 
clinical studies have shown that growth factor therapies are well tolerated by patients, there is a 
pronounced need to improve the efficacy of these treatments to maximize the benefit of these 
therapies and make them cost effective for our healthcare system.  
 Here, we hypothesized that the diabetic state prevents the effectiveness of growth factor 
therapies through alterations in expression and proteolytic degradation of receptors and co-
receptors. This concept is supported by reduced efficacy of growth factors in many clinical trials 
for enhancing healing in chronic wounds[8] compared to healthy animals.[9] In addition, our group 
recently examined the expression of growth factor receptors and co-receptors in the heart and 
skeletal muscle of diabetic mice and found a significant loss in syndecan-4 and other cell surface 
proteoglycans that serve as co-receptors for growth factors including FGF-2, VEGF-A and 
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PDGF-CC.[10] We have also shown that diabetes and other disease states increase expression of 
heparanase, an enzyme that cuts the heparan sulfate chains and increases shedding of cell surface 
proteoglycans.[11, 12] In this study, we demonstrate that there is a reduction in syndecan-4 in the 
skin of human patients with type 2 diabetes. We examined whether delivery of syndecan-4 
proteoliposomes (“syndesomes”) could overcome the inherent resistance to growth factor 
signaling to enhance the healing of wounds in diabetic mice with severe disease. Our studies 
show that syndesomes delivered locally from alginate wound dressings markedly enhanced the 
efficacy of FGF-2 therapy for wound healing in the diabetic disease state through multiple 
mechanisms.  
 
Page 5 of 48 
  
MATERIALS AND METHODS 
Human samples. Human skin samples were obtained from the Glasgow Caledonian University 
Skin Research Tissue Bank, Glasgow, UK. The tissue bank has NHS research ethics to supply 
human skin for research (REC REF: 11/S1402/2). The samples were already paraffin embedded 
before being shipped to us. The samples were sectioned using a microtome to obtain 6 µm thick 
sections. The slides were for syndecan-4 (Abcam) using the Envision+ Dual Link Kit (Dako). 
The details of the staining procedure are described in a later section. We used 9 samples in both 
diabetic and non-diabetic groups.  
 
Recombinant syndecan-4 protein production. HEK293-T cells were transduced with a custom 
made plasmid with full-length syndecan-4 gene using a lentiviral transduction system. The 
syndecan-4 overexpressing stable cells were grown in high glucose DMEM with 10% FBS, 5% 
Penicillin-Streptomycin and 5% L-glutamine. The cells were lysed using a lysis buffer 
containing 1% Triton X-100 and protease inhibitors (Roche). The cell lysate was sonicated, 
vortexed and then centrifuged (25000 x g). The supernatant was used for protein purification by 
a HiTrap Q HP column (GE Healthcare) on a FPLC (Amersham Biosciences). Pure protein was 
confirmed by silver stain and a western blot probing for the syndecan-4 protein, and the protein 
concentration was quantified using a BCA assay (Thermo Scientific).  
 
Preparation of syndesomes. The lipids used for the preparation were 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), cholesterol, 
and sphingomyelin (Avanti Polar Lipids). Briefly, a solution mixture of the four lipids at 10 
mg/ml concentration was made in a volumetric ratio of 2:1:1:1 chloroform. The mixture was 
prepared in a round bottom glass flask and the chloroform was removed using a rotatory 
evaporator for 1 hour followed by treatment with stream of argon gas for 15 minutes. Once all 
the chloroform was removed, the lipid film was resuspended in a HEPES-buffered salt solution 
by vortexing, sonicating, and freeze thawing three times each in order. This lipid solution was 
then extruded through a 400-nm polycarbonate membrane filter (Avestin) to generate liposomes. 
Syndecan-4 protein was added to the liposome suspension to a final concentration of 50 µg/ml. 
To this solution we added 1% n-octyl-β-D-glucopyranoside to permeablize the liposomes and 
incorporate the protein. The detergent was then removed through serial dilution, extensive 
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dialysis and treatment with BioBeads (SM-2, Bio-Rad). The amount of protein incorporated into 
the liposomes was measured using a BCA assay (Thermo Scientific). FGF-2 (Peprotech) was 
mixed with the syndesomes when they needed to be delivered together. 
 
Liposome characterization. The size and dispersion of the syndesomes and isolated syndecan-4 
was characterized by dynamic light scattering (Malvern Zetasizer Nano ZS). The instrument was 
calibrated using 54-nm diameter polystyrene particles. The syndesomes were diluted 1:1000 to 
fit the detection region of the instrument and then aliquoted into a polystyrene cuvette to run in 
the machine. The results were an average of 50 size measurements. For imaging with cryo-
electron microscopy, the liposomes were plunge-frozen in liquid ethane on carbon holey film 
grids as previously described (R2x2 Quantifoil®; Micro Tools GmbH, Jena, Germany) [13]. The 
grids were transferred to a cryo-specimen holder (Gatan 626) under liquid nitrogen and put in a 
microscope (JEOL 2100 LaB6) operating at 200 keV. Grids were maintained at close to liquid 
nitrogen temperatures during EM session (-172°C to -180°C). Liposomes were imaged at 
20,000x EM magnification with a 4kx4k slow-scan CCD camera (UltraScan 895, GATAN, Inc.) 
using low-dose imaging procedure. Images were acquired with less than 20 electrons/Å2 electron 
dose.  
 
Preparation of syndesome-releasing alginate gels. We created a 6.35 mm diameter alginate disk 
using a custom-designed mold to implant in the wound. Equal volumes of 4% sodium alginate 
(Sigma) solution and 0.85% NaCl solution were mixed and the syndesomes and/or FGF-2 were 
added to this solution. The alginate solution was pipetted into the mold and then cross-linked 
with a solution of 1.1% CaCl2 for 1 hour at 4°C. We used 5 µg of FGF-2 and/or 0.5 µg of 
syndecan-4 protein according to the sample (control, FGF-2, S4PL or S4PL with FGF-2) in each 
disk implanted. For the release studies, 2 alginate disks with different treatments were placed in a 
scintillation vial containing 10ml of 1X PBS with Ca2+ and Mg2+. At every time point, 200ul of 
buffer was aliquoted from the scintillation vial and frozen while replacing 200ul of fresh buffer 
into the vial. The buffer samples at each time point were analyzed using FGF-2 ELISA for the 
amount of FGF-2 released cumulatively over the course of a week. The alginate disks were flash 
frozen in liquid nitrogen (-195C) and lyophilized overnight (-110C, 0.0005mbar) in scintillation 
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vials. The final freeze-dried gels were sputter coated with gold discharge for 30 seconds and then 
imaged using the scanning electron microscope (FEI Quanta 650 ESEM) at 10kV. 
 
Electric cell-substrate impedance sensing (ECIS) assay for cell migration. The cells used for 
the assay were adult dermal fibroblasts and adult epidermal keratinocytes, both from either 
healthy or type 2 diabetic donors (Lonza). Fibroblasts were grown in high glucose DMEM 
(Gibco) with Pen-Strep, 10% FBS, L-glutamine and fibroblast supplements (Lonza) while the 
keratinocytes were grown in MCDB-131 (Gibco) with Pen-Strep, 10% FBS, L-glutamine and 
keratinocyte supplements (Lonza). However when the cells were used for the experiment, the 
media was serum free. The 96W1E+ plates (96 wells) were first coated with 100 µl of 2mM 
Cysteine (Sigma) per well for 30 minutes followed by a quick wash with 1X PBS. The wells 
were then coated with 40 µl/well of fibronectin (Sigma) at 8 µg/ml overnight. After a quick 1X 
PBS wash, to remove unbound fibronectin, the cells were plated at 10,000 cells per well and 
allowed to attach, while the plate was placed on the Z-Theta instrument (ECIS), which created an 
electric fence around the electrode. The cells were allowed to settle and attach for 4 hours. 
Finally, the electric fence was turned off and the cells were allowed to migrate over the electrode. 
The substrate impedance and resistance were measured every 48 seconds at a frequency of 
40,000Hz. Six wells per treatment group in the migration assay were used. 
 
Fibroblast invasion assays. Human adult dermal fibroblasts (Lonza) were used in the Trevigen 
Inc. The fibroblasts were cultured in with high glucose DMEM with Pen-Strep, 10% FBS, L-
glutamine and fibroblast supplements (Lonza). The cells were starved for 24 hours in media 
without serum before the assay in high glucose DMEM with Pen-Strep, L-glutamine (no FBS). 
The treatments were added to this starvation media. Collagen-I cell invasion assay to assess the 
invasion potential of the fibroblasts in the presence of various treatments. The top invasion 
chamber was coated with collagen I and kept to attach overnight. The cells were plated in each 
well at a concentration of 106 cells/ml in the top chamber and treatments were added to the 
bottom chamber. The cells were incubated with the treatments for 24 hours and then the top 
chambers were moved to the assay plate with Calcein-AM and cell dissociation solution. This 
solution detaches the cells that have invaded from the top chamber to the bottom side. Finally the 
assay plate was read without the top chamber at 485 nm excitation and 520 nm emission. The 
intensity is a measure of the amount of cell invasion through the collagen I layer. Six wells per 
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treatment group in the invasion assay were used. 
 
Intracellular trafficking of FGF-2 using co-localization with Rab adapter proteins. The Rab5-
GFP, Rab7-GFP and Rab11-GFP plasmids were provided by Dr. Mukhopadhyay and have been 
previously described.[14] The Rab4-GFP and Rab9-GFP constructs were purchased from 
Addgene.[15] FGF-2 (Peprotech) was conjugated with Alexa Fluor 594 (Life Technologies) using 
the heparin column that binds the active site of FGF-2 preserving its biological activity.[10, 16] 
HEK293Ta cells plated on 8-well glass slides (ibidi) at 10000cells/well and were transfected 
with the above-mentioned plasmids using DNA HTS jetPEI transfection reagent (Polyplus 
transfection™) using standard protocol. Twenty four hours post transfection, the cells were 
treated with AF594 tagged FGF-2 (1 µl) and/or syndesomes (1 µl). The cells were fixed at 15, 30, 
60 and 120 minutes using 4% paraformaldehyde (Electron Microscopy Sciences) and washed 
three times with PBS for 10 minutes each. The cell nuclei were stained with DAPI (Vector Labs) 
and mounting media was added in the wells. The slides were then imaged using the laser 
scanning confocal microscope (Zeiss LSM710). The percentage of Rab-GFP labeled endosomes 
containing AF594 tagged FGF-2 was calculated as follows: each cell was divided into four 
roughly equal quadrants and one of the quadrants was chosen for quantification randomly (using 
RAND function of Excel). The total number of Rab-GFP labeled endosomes and endosomes that 
co-localize with AF594 tagged FGF-2 in the chosen quadrant were counted to calculate the 
percentage of co-localization. For each time point and treatment group, 10 cells were analyzed 
using Metamorph (Molecular Devices). 
 
Animal studies. All animal experiments were performed with the approval of the Institutional 
Animal Care and Use Committee (IACUC) of University of Texas at Austin, and in accordance 
with NIH guidelines “Guide for Care and Use of Laboratory Animals” for animal care. All the 
animal experiments were performed on a diabetic, obese and hyperlipidemic mouse model 
(ob/ob). All the ob/ob mice (B6.Cg-Lepob/J) were purchased from the Jackson Laboratory. All 
animals were fed a high fat diet (Research Diets - D12331) for 10 weeks before performing 
wound healing surgeries.  
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Excisional wound healing model. To examine wound healing in the diabetic and obese mice we 
used a full-thickness excisional model with a splint to prevent wound contraction.[17] A sterile 5-
mm biopsy punch was used to outline a pattern of four wounds, two on either side of midline on 
the dorsum of the mouse. A splint was fashioned using 0.5-mm thick silicone sheet and was 
placed so that the wound was centered within the splint. The splint was immobilized in place 
using 6-0 nylon sutures and cyanoacrylate glue to prevent wound contraction. Alginate gel disks 
encapsulating syndesomes and/or FGF-2 were then applied directly to the region of the open 
wound. A single sheet of Tegaderm was used to cover all the wounds. Photographs of the 
wounds were taken on days 0, 7 and 14. The animals were euthanized at 2, 6 and 14 days, and 
the wounds were biopsied with a 10-mm biopsy punch. The tissues were snap frozen in liquid 
N2-chilled isopentane and used for further analysis. 
 
Laser speckle contrast imaging of tissue perfusion. A custom Laser Speckle Contrast Imager 
(LSCI) was used to image the tissue blood flow as previously described.[18] Briefly, a near 
infrared (785nm, 50mW) laser diode (Thor Labs) was used to illuminate the wounds on the back, 
and the speckle was captured using a Zoom-7000 lens (Navitar) linked to a Bassler CCD camera 
(Graftek). The wounds were imaged right after surgery (day 0), and at day 7. All wounds were 
imaged simultaneously within the laser field to allow the quantification of relative perfusion.  
 
Histological analysis and immunostaining. Tissues from the in vivo experiments were 
embedded in paraffin and 6 µm thick sections were produced using a microtome. The slides were 
stained with H&E or Movat’s pentachrome stains. The wound healing samples were also 
immunostained using the Envision+ Dual Link Kit (Dako North America, Inc.) for cytokeratin 
(Abcam), CD86 (Bioss), CD163 (Bioss) or von Willebrand factor (Dako). The details about the 
antibodies are mentioned in the Supplemental Table S2. Briefly, the slides were de-paraffinized 
and placed in a bucket with Antigen Retrieval Solution (Dako), and placed in the microwave 
(1250 W) for 2 minutes and 40 seconds. Then the bucket was placed in a water bath maintained 
at 80°C for 3 hours. This reduces the background staining significantly. The slides were cooled 
in solution for 20 minutes and washed in PBS twice for 5 minutes each. Then they were blocked 
in 20% fetal bovine serum in PBS for 45 minutes at room temperature. The slides were then 
washed two times for 5 minutes in PBS and a circle was drawn around the section with a 
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hydrophobic pen. The sections were peroxide blocked with dual enzyme block solution (Dako) 
and incubated for 30 minutes. This was followed by 3 washes in PBS for 5 minutes each. After 
that, the primary antibody in antibody diluent (Dako) was applied to the sections and the slides 
were incubated at 4°C for overnight. On the following day, the sections were washed in PBS 
thrice and then the peroxidase labeled polymer (HRP) was added and the slides were incubated 
for 30 minutes at room temperature. Following the incubation, nine washes with PBS were done 
after with a wait of 5 minutes after every 3 washes. In the meantime, the DAB+ solution was 
prepared and added to the sections once washing had been completed. The incubation period was 
optimized according to the intensity of staining. After 3 washes in PBS, the slides were stained in 
Mayer’s Hematoxylin for 3 minutes. Finally they were washed in distilled water three times, 
mounted with an aqueous mounting media and covered with a cover glass. For each treatment 
group we analyzed 5 slides per sample (total 40 slides) each with 2-3 sections. 
 
Wound digestion and flow cytometry analysis. The wounds (day 2 and 6) were excised out using 
a 10 mm sterile biopsy punch and cut from the center into two disc shaped pieces. Half of the 
tissue was used for cryosectioning and histology. The other half was digested[19] in an enzyme 
cocktail and used for the flow cytometry experiments. The single cell suspension from the 
wound tissue was maintained at 106 cells/ml in the FACS staining buffer (BD). The samples 
were blocked with 1 µg/ml (final concentration) of Rat IgG2b for 20 minutes on ice. The cells 
were then stained with the following antibodies for 30 minutes on ice: anti-mouse F4/80 (Pe-
Cy7), anti-human CD206 (FITC) and anti-mouse CD86 (Biotin; refer Supplemental Table S2 
for additional antibody details). Two washes were performed with FACS staining buffer. The 
PerCP streptavidin antibody was used to stain the samples for another 20 minutes on ice. The 
samples were finally washed twice with the FACS staining buffer and resuspended in 1 ml buffer. 
The samples were fixed with 500 µl of cytofix buffer (BD Biosciences) and stored at 4°C. The 
samples were run together on the BD LSRFortessa cell analyzer recording at least 10,000 events 
in every sample. The final data was analyzed using FlowJo software (FlowJo, LLC). 
 
Quantification of wound closure and immunohistochemical staining. The macroscopic 
pictures of the wounds taken during surgery at day 0, 7 and 14 were used for the wound closure 
analysis. The Meiji stereo-zoom surgical dissection microscope with a Nikon D70 camera was 
Page 11 of 48 
  
used to take the pictures of the wounds. The camera was height was fixed throughout the 
experiment and the inner diameter of the silicone splints (6 mm) served as the parameter to 
normalize the wound area. The images were quantified using Metamorph (Molecular Devices) 
and were compared to the day 0 area (100% open). The immunostained slides were imaged using 
a Meiji brightfield microscope with CCD camera at 10X, 20X and 40X magnifications. The 
images from each treatment group with five sections were used for the quantification. The 
number of cells that were positively stained was quantified in comparison to the total cells. 
 
Measurement of cytokines in wound lysates. The wound tissues were frozen in liquid N2 cooled 
isopentane. The samples were sectioned into one-micron thick sections using a cryostat. The 
sections were solubilized using the lysis buffer with 1% Triton-X 100 and protease inhibitors. 
The lysate was centrifuged at 25,000g in a refrigerated centrifuge and the supernatant was 
applied to a Ray Biotech Mouse Inflammation Antibody Array 1 (G-series). The arrays were 
processed according to the manufacturer’s instructions. The images were scanned using a laser 
scanner with the Cy3 channel. The intensity data was background subtracted with the negative 
controls and normalized with respect to the positive controls. 
 
Statistical Analysis. Comparisons between two groups were performed using a two-tailed 
Student’s t-test. Multiple comparisons between groups were analyzed by two-way ANOVA 
followed by a Two-sided Dunnett post-hoc testing. For the wound closure data, the test groups 
compared with a two-tailed p-value of < 0.05 were considered as statistically significant. 
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RESULTS 
Syndecan-4 is reduced in the skin of patients with type 2 diabetes. We hypothesized that the 
long-term disease state of diabetic patients may reduce the levels of syndecan-4 and thus reduce 
the effectiveness of growth factor therapies in this patient population. To examine whether there 
was loss of syndecan-4 in diabetic humans, we collected skin samples from patients with type 2 
diabetes and non-diabetic patients (Supplemental Table S1), and then performed 
immunostaining of syndecan-4 in these tissues. We found a significant reduction in the staining 
of syndecan-4 in both the overall tissue samples (Fig. 1A) and in the blood vessels (Fig. 1B). We 
next aimed to examine whether syndesomes would be able to overcome enhance FGF-2 activity 
in the context of the diabetic disease state in which there is a loss of syndecan-4 and reduced 
responsiveness to growth factor therapy. The overall concept was to deliver FGF-2 with 
liposomes incorporating syndecan-4 (syndesomes) from a non-adhesive alginate wound dressing 
that could be applied to non-healing wounds in diabetic patients for enhancing wound healing 
(Fig. 2).  
Synthesis and characterization of syndesomes and alginate gels. We created syndesomes by 
isolating recombinant syndecan-4 proteins and fusing them into the membrane of liposomes 
using a detergent extraction method. We confirmed the purity of the syndecan-4 protein using 
SDS-PAGE with silver staining as well as western blotting for syndecan-4 (Supplemental Fig. 
S1). A high molecular weight smear was observed in the blots implying that majority of the 
syndecan-4 was glycosylated. We also measured the size distribution of the isolated recombinant 
protein and the syndesomes using dynamic light scattering. This analysis demonstrated that the 
recombinant protein in isolation had significant self-association and separated into three distinct 
peaks, most likely representing protein aggregate formation and varying degrees of glycosylation 
(Fig. 1D). In contrast, the syndesomes had a single distinct peak corresponding to the 
approximate liposome diameter of 400 nm. In addition, we confirmed the integrity of the 
liposomes by performing cryo-electron microscopy (cryo-EM) analysis of the liposomes and 
syndesomes (Fig. 1E). To further confirm the incorporation of the protein into the lipid 
membrane, we examined the change in size of the liposome with varying amounts of protein 
using transmission electron microscopy (TEM). We found that the liposome size increased with 
increasing amounts of protein incorporation (Supplemental Fig. S2A, B). In addition, the zeta 
potential of the liposomes was altered by syndecan-4 incorporation (Supplemental Fig. S2C). 
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To create a local delivery platform for release of the syndesomes into the wound, we 
encapsulated the compounds into alginate disks (Fig. 1F). The release kinetics of FGF-2 from 
the alginate was similar over the implantation time of 7 days (Fig. 1G). We confirmed that the 
proteoliposomes were released intact by measuring the size of the released liposomes before and 
after release with DLS (Supplemental Fig. S3).  
 
Syndesomes enhance keratinocyte migration, and reduce both fibroblast invasion and 
migration. We next assessed whether exogenous delivery of syndecan-4 could enhance the 
migration and invasion of dermal fibroblasts and keratinocytes, two key cellular effectors of 
wound healing. Keratinocytes from non-diabetic donors showed a nearly four-fold increased in 
migration with treatment with the syndecan-4 proteoliposomes at the optimal concentration 
(0.2% S4PL; Fig. 2A). Surprisingly, the syndesomes alone were more effective at inducing 
migration than in combination with FGF-2 but migration was increased under both conditions. 
Keratinocytes from diabetic patients showed only a moderate increase in migration in the groups 
treated with both syndecan-4 and FGF-2 (Fig. 2B). Higher doses of syndecan-4 with FGF-2 
demonstrated a reduction in migration for both cell lines. In contrast, treatment with the 
syndesomes appeared to decrease migration of normal dermal fibroblasts (Fig. 2C) and did not 
alter the migration of fibroblasts from diabetic patients (Fig. 2D). We also measured the invasion 
of fibroblasts through a collagen gel under various treatment conditions and found a moderate 
reduction in migration with syndesome treatment in diabetic fibroblasts and no significant 
difference between the treatment groups in the normal fibroblasts (Supplemental Fig. S4). 
 
Syndesomes increase endosomal processing and recycling of FGF-2 to the cell surface. FGF-2 
can be internalized by receptor-mediated and heparan sulfate proteoglycan-mediated 
mechanisms. The FGF receptor-1 (FGFR1) is endocytosed into early endosomes in a both a 
caveolin and clathrin-dependent mechanisms, from which it can be recycled through both the 
slow and fast pathways, or shuttled to the lysosomal compartment for degradation.[20] We next 
investigated how syndesomes altered the endosomal processing of FGF-2 to better understand 
the mechanism of action. Cells were transfected with plasmids containing GFP conjugated Rab 
proteins to label specific endosome subsets and then treated with fluorescently labeled FGF-2. 
We quantified the percentage of endosomes that co-localized with labeled FGF-2 for each time 
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point. We found a significant increase in percentage of Rab5 (early endosome marker) labeled 
endosomes with FGF-2 in the syndesome with FGF-2 group at all the time points indicating 
higher FGF-2 uptake (Fig. 3A). The level of FGF-2 that co-localized with the late endosomal 
marker Rab7 (late endosomal marker) remained low throughout the experiment, showing 
significant differences between the treatment groups only at 120 minutes (Fig. 3B). There was an 
increase in the percentage of FGF-2 positive Rab11 endosomes (late recycling endosomes) at all 
time points when we compare the FGF-2 only treatment with the syndesomes with FGF-2 
treatment (Fig. 3C). Thus, the majority of the FGF-2 that was processed through endosomal 
pathways was likely getting recycled to the plasma membrane surface through the Rab11 
pathway rather than getting degraded by the Rab7 pathway. This hypothesis was supported by a 
significant increase in the Rab4 endosomes (early recycling endosomes) co-localizing with FGF-
2 in the syndesome with FGF-2 group (Fig. 3D). We did not see any differences in the 
colocalization of Rab9 endosomes (late endosomes that transport to trans-golgi network) with 
FGF-2 (Fig. 3E).  
 
Syndesomes improve wound healing in obese, diabetic mice. We next tested the effectiveness of 
syndesome therapy for enhancing wound healing in the diabetic ob/ob mouse model. Previous 
studies have shown that these mice have reduced wound closure[21] and have reduced 
responsiveness to FGF-2 [22], when placed on a high fat diet. To examine whether syndesomes 
could enhance wound healing in a diabetic and obese animal model we created full-thickness 
wounds on the dorsal surface of these mice and attached a silicone splint around the wound using 
glue and sutures to prevent contraction. We created alginate wound dressings that matched the 
size of the wounds using a custom-designed mold (Fig. 4A). The gels were replaced seven days 
after the initial wounding and the mice were allowed to heal for an additional seven days. A 
macroscopic analysis of wound closure revealed a two-fold decrease in wound size after 14 days 
in the syndesomes with FGF-2 treatment compared to FGF-2 alone (Fig. 4B, 4C and 
Supplemental Fig. 5A, 5B). We performed immunostaining for cytokeratin and measured the 
regeneration of the epidermis beyond the initial wound defect. A morphometric quantification 
showed increase re-epithelization in the syndesome with FGF-2 group over the other treatment 
groups (Fig. 4D, 4E). Analysis of the granulation tissue area revealed similar levels of 
granulation tissue in all wounds with a slight increase in the FGF-2 treated samples 
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(Supplemental Fig. S5C, S5D). A histological analysis of the wound beds demonstrated 
increased cellular infiltration in the syndesome with FGF-2 group in comparison to the other 
groups including the syndesomes alone (Fig. 4F).  
 
Syndesomes increase perfusion in the healing wound bed. We measured the blood perfusion in 
the wounds immediately after wounding and seven days later. Due to the variation in healing 
between the groups we did not measure blood perfusion in the wounds at day 14 following 
wounding. We found that there was significant increase of blood perfusion in the syndesomes 
with FGF-2 compared to all other groups at seven days (Fig. 5A, B). After 14 days, we harvested 
the wound beds and performed immunostaining for endothelial cells. This analysis showed 
increased blood vessels in the wound bed of the FGF-2 with syndesome treated group in 
comparison to FGF-2 alone and other groups (Fig. 5C, D).  
 
Syndesomes enhance wound healing phenotype in macrophages. Macrophages are key players 
in the wound healing cascade through the regulation of inflammation and healing responses. 
Macrophages can express a continuum of phenotypes that are often broadly classified into M1 
macrophages with pro-inflammatory activities or M2 macrophages that orchestrate matrix 
deposition and wound healing. We examined the expression of CD86 (M1 marker) and CD163 
(M2 marker) using immunostaining of histological sections from the mice treated with 
syndesome-incorporating alginate wound dressings after 14 days. This analysis demonstrated a 
decrease in the expression of CD86 with syndesome treatment (Fig. 6A, B). In addition, the 
levels of the M2 marker CD163 were increased in the wound beds (Fig. 6C, D). Interestingly, 
the modulation of the marker expression was present in both the syndesomes with FGF-2 and in 
the S4PL alone groups, suggesting that the syndesomes were directly inducing 
immunomodulation in the wounds.  
To further examine whether syndesomes could modulate the immune response during 
healing, we treated ob/ob mice with the various wound dressings and harvested the wound 
tissues at two and six days following wounding. We digested half of the harvested wound beds 
into a single cell suspension and used flow cytometry to quantify the expression of macrophage 
markers. Six days after wounding, we found a decreased number of macrophages (F4/80+ cells) 
and increased expression of the M2 marker CD206 in the syndesomes with FGF-2 treated 
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wounds in comparison to FGF-2 only treated wounds (Fig. 6E, 6F). We took the other half of the 
wound bed from day two and six after wounding, lysed the tissue, and performed an analysis of 
the cytokines in the wound using ELISA and cytokine antibody arrays. The cytokine antibody 
array at day 6 revealed many changes in the cytokine concentrations compared to the control 
group (Fig. 6G; Supplemental Fig. S6). The ELISA revealed similar levels of IL-1α, an 
inflammatory cytokine released by many cell types including neutrophils and macrophages, 
between the four treatment groups (Fig. 6H). We also observed an increase in IL-4 and IL-6 in 
the syndesomes with FGF-2 treated wounds over FGF-2 alone treated wounds (Fig. 6I, 6J). Both 
of these cytokines have been linked to alternative activation of macrophages and this finding is 
consistent with the increased CD163 expression and decreased CD86 expression in the 
syndesomes with FGF-2 treatment group. In addition, there were increased levels of stromal cell-
derived factor-1 (SDF-1), IL-1β, monokine induced by gamma interferon (MIG/CXCL9) and IL-
2 in the syndesomes with FGF-2 group versus wounds treated with FGF-2 alone (Supplemental 
Fig. S7; Supplemental Table S3). Previous studies have shown that exogenously applied SDF-1 
or IL-2 enhances wound healing [23]. A proteomic analysis of chronic pressure ulcers in human 
patients found that MIG increases in chronic ulcers that heal but remains constant in those that 
do not heal.[24] 
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DISCUSSION 
Clinical trials using growth factor therapies to enhance diabetic wound healing have 
produced poor or equivocal results.[8] Here, we hypothesized that the current approach of 
delivering growth factors is not effective because it does not account for the changes in tissue 
responsiveness due to disease. We examined skin samples from patients with type 2 diabetes and 
found that the levels of syndecan-4 were reduced in both the overall skin and blood vessels 
relative to non-diabetic patients. We then tested the ability of syndecan-4 liposomes in 
controlling wound healing in in vitro and in vivo studies. Overall, the delivery of syndecan-4 
protein with FGF-2 markedly improves many indices of wound healing including the migration 
of keratinocytes, wound closure and shifting the macrophages towards the wound healing M2 
phenotype (Fig. 7). In addition, our results support the validity of the concept that by delivering 
co-receptors downregulated by a disease state, one can markedly improve the efficacy of a 
delivered therapeutic ligand.  
A key point of our study is that the diabetic disease state must be considered when 
developing protein therapeutics for wound healing. Many clinical trials have been performed for 
therapies to improve the healing of chronic wounds based on the findings in large animal models 
in the absence of diabetics. In fact, the most commonly used preclinical wound model is 
performed in the non-diabetic pig, a model that has relatively rapid wound healing and does not 
have healing resistant wounds. Our findings that diabetic patients have reduced syndecan-4 in 
blood vessels of the skin illustrates the profound difference that exists between healthy patients 
and those that are prone to developing chronic wounds. We hypothesize that much of this loss of 
syndecan-4 can be attributed to the shedding and degradation of the protein by diabetes-induced 
changes in protease activity. This hypothesis is supported by the loss of the glycans observed in 
diabetes[25] and that syndecan-4 is shed by factors increased in diabetes including reactive 
oxygen species,[26] proteases[27] and inflammation.[28] This concept is also supported by our prior 
studies in diabetic mice in which we found a significant reduction in many of the growth factor 
receptors and co-receptors in the skeletal muscle and myocardium.[10] Therefore, we would argue 
that it is essential to perform preclinical studies for wound healing in animal models that 
represent the disease states that commonly accompany non-healing wounds in patients. As 
diabetic porcine models have been used extensively in the study of atherosclerosis,[11] it would 
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seem that there is both an economic and ethical imperative to use these types of model in 
preclinical studies of wound healing to reduce the risk of failed clinical trials.  
While previous studies have shown endogenous syndecan-4 plays a role wound healing, 
it is surprising that delivery of exogenous syndecan-4 protein is able to enhance keratinocyte 
migration and wound healing to the extent we observed in our studies. Syndecan-4 is induced in 
the skin following acute wounding in both mice and neonatal humans.[29] Mice lacking syndecan-
4 have delayed wound healing and impaired angiogenesis.[30] Therefore, in the context of wound 
healing there are likely multiple benefits to increasing syndecan-4 in the wound bed. Several 
prior studies have also supported a role for syndecan-4 in wound healing independent of its 
activity as a co-receptor for FGF-2. Endogenous syndecan-4 expression promotes fibroblast 
migration and regulates integrin signaling and small GTPases during wound healing.[31] In 
addition, syndecan-4 also enhances keratinocyte migration[32] and is necessary for migration of 
fibroblasts in fibrin gels.[33] Our previous work has shown that delivery of syndecan-4 in a 
proteoliposome was more potent in inducing cell proliferation/migration, activation of ERK1/2 
signaling pathway, in vitro endothelial tube formation, nuclear trafficking of growth factors and 
angiogenesis in comparison to the free syndecan-4 protein.[16] In our studies showed increased 
migration in keratinocytes and decreased invasion activity when the cells were treated with 
exogenous syndecan-4 protein in a proteoliposome. This would suggest that the developed 
treatments would be able to synergistically enhance cell therapies, including those delivered 
from electrospun materials.[34] With exogenous delivery of the protein there is the possibility that 
the syndecan-4 works as a competitive inhibitor to the binding of the endogenous syndecan-4. 
Whether this occurs is likely a function of concentration of the ligand bound by syndecan-4, the 
concentration of the relevant receptor and the concentration of endogenous syndecan-4. In this 
case, it would suggest there is additional capability in keratinocytes to have enhanced FGF-2 
signaling through the addition of syndecan-4 but that additional syndecan-4 serves as a 
competitive inhibitor for fibroblasts undergoing invasion.  
Our current study suggests that a major activity of syndesomes is to enhance FGF-2 
recycling through endosome-mediated mechanisms. Syndecan-4 is a key co-receptor in the FGF-
2 and FGFR-1 signaling cascade[35] where the heparan sulfate chains bind to FGF-2, and 
syndecan-4 dimerizes to aid as a co-receptor to FGFR-1. Furthermore, FGF-2 and FGFR-1 reside 
in the same endosomal compartment as syndecan-syntenin-PIP2 complex.[36] Both FGF-2 and 
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FGFR-1 are taken up through the clathrin-mediated pathway, followed by trafficking to the early 
and late endosomes.[37] Syndecan-4 also recycles to the surface through both early and late 
endosomes[38] In our studies, we found significantly higher amounts of FGF-2 in the early 
endosomes (Rab5 positive). This finding would be expected with overexpression of the 
syndecan-4 gene, as an increased amount of syndecan-4 would facilitate receptor binding and 
uptake through pinocytosis.[39] However, as the proteoliposomes used do not undergo direct 
membrane fusion it is less clear how these changes might occur with syndesome treatment. We 
hypothesize that syndesomes increase FGF-2 uptake by enhancing the binding of FGF-2 to its 
receptor through the heparan sulfate chains of syndecan-4 and then facilitating the uptake of 
additional FGF-2 bound to syndecan-4 in the liposomal membrane during internalization. This 
hypothesis is consistent with our previous finding that free syndecan-4 is not as effective in 
enhancing FGF-2 uptake, signaling and angiogenesis.[16] It would also be consistent with our 
finding of increased recycling of FGF-2 through the slow (Rab11) and fast (Rab4) mechanisms 
that we observed in our studies. This increased recycling may be the result of FGF-2 bound 
syndecan-4 being trafficked back to the surface after being internalized through the syndesome 
construct. This recycled FGF-2 would therefore be available for additional receptor 
interactions,[40] making the FGF-2 more effective for an equivalent dose and leading to a 
prolonged effect.  
 Our study supports that the delivery of exogenous syndecan-4 protein drives wound 
macrophages toward the M2 phenotype. Wound healing is a delicate balance between the 
necessary inflammation that facilitates wound closure and angiogenesis, and excessive 
inflammation that can impede the wound healing process. A recently proposed scheme classifies 
macrophages as ranging in a phenotypic continuum from inflammatory (M1) to “alternatively 
activated” (M2) phenotypes.[41] However, the exact nature of these phenotypic states remains 
unclear and multiple other sub-phenotypes have been hypothesized. Efficient wound healing 
requires both the necessary inflammatory state and the pro-fibrotic, scaffold generating state. 
Thus, one hypothesis is that chronic non-healing wounds can arise when too much or too little 
inflammation is present, and scar formation can occur when the “healing” response is overactive 
and leads to wound fibrosis and scarring.[42] Within the wound environment, various subsets of 
macrophages have been associated with inflammation or with fibrosis but the strict definitions of 
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M1 and M2 phenotypes do not adequately characterize the full complexity of wound 
macrophage phenotypes.[43]  
The detailed mechanistic role of syndecan-4 in macrophage phenotype is unknown but 
several studies support that it is functionally involved in LDL uptake,[44] signaling in response to 
RANTES and SDF-1,[45] and the response to endotoxic shock.[46] Our study demonstrated 
increased M2 macrophage phenotype at early time points in the wounds, suggesting that 
syndesomes can alter the initial immune response to the wound. The presence of increased M2 
macrophages would have a number of benefits for healing in chronic wounds including 
enhancing angiogenesis and the production of pro-healing cytokines.[47] Consistent with M2 
macrophage phenotype, we observed an increase in cytokines associated with M2 macrophages 
(IL-4 and IL-6) as well as a number of pro-healing cytokines including IL-2 and SDF-1. 
Topically applied IL-4 can increase wound healing in mice and facilitated macrophage 
differentiation into the M2 phenotype.[48] IL-6 is also essential for wound healing and facilitates 
keratinocyte migration, wound contraction and macrophage infiltration.[49] In addition, both IL-2 
and SDF-1 have been shown to increase wound healing in small animal models.[23] Thus, our 
studies demonstrate that syndesomes act in the early stages of wound healing to enhance the 




In summary, we have shown that there is a reduction of syndecan-4 protein in diabetic 
patients and that syndesomes enhance FGF-2 therapy in the context of wound healing in the 
diabetic disease state. Our studies support that the syndesomes increase keratinocyte migration, 
endosomal recycling of FGF-2, and enhance the M2 macrophage phenotype and production of 
pro-healing cytokines. While it is likely that there exist many other mechanisms of growth factor 
resistance diabetes it is encouraging that significant improvements in therapeutic potential can be 
garnered by targeting only the FGF-2/syndecan-4 signaling pathway. Further studies are needed 
to both understand the detailed mechanisms of growth factor resistance and to further develop 
therapeutics to be effective in disease states. In this context, our therapeutic paradigm of 
delivering co-receptors as enhancers of growth factor activity may be applicable to a number of 
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other biological systems in which disease modifies the responsiveness of the tissue such has 
hyperlipidemia and metabolic syndrome.  
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FIGURE LEGENDS 
Figure 1. Measurement of syndecan-4 levels in the skin of diabetic and healthy patients; 
synthesis and characterization of syndesomes. (A) Expression of syndecan-4 in human skin 
from diabetic and non-diabetic patients for the overall skin histology. Bar = 25 µm. (B) 
Expression of syndecan-4 in the blood vessels in the human skin. Bar = 25 µm. (C) Diagram of 
incorporating syndesomes and FGF-2 in an alginate wound dressing. (D) Dynamic light 
scattering analysis for syndecan-4 protein and liposomes incorporated with syndecan-4 
(syndesomes). (E) Cryo-electron microscopy images liposomes and syndesomes. Bar = 400 nm. 
(F) Scanning electron microscopy images of desiccated alginate disks with various treatments. 
Bar = 100 µm. (G) Release kinetics of the FGF-2 from alginate beads containing syndesomes 
with FGF-2 or FGF-2 alone. *Statistically different from the non-diabetic patient group (p < 0.05, 
n = 9). 
 
Figure 2. Effect of syndesomes on migration of keratinocytes and fibroblasts. (A) Migration 
of keratinocytes from a non-diabetic donor at the 20 hours, with various treatments shown as bar 
graphs (left). Line graphs showing the time course of the change of resistance for the four 
treatment groups (right). Note that S4PL concentration is 0.4%. (A) Migration of keratinocytes 
from a diabetic donor at the 20 hours, with various treatments shown as bar graphs (left). Line 
graphs showing the time course of the change of resistance for the four treatment groups (right). 
Note that S4PL concentration is 0.4%.  (C) Change in resistance due to migration at 20 hours in 
dermal fibroblasts from a non-diabetic donor, shown as bar graphs (left). Line graphs show the 
time course of the change of resistance for all the treatments with 0.4% S4PL concentration 
(right). (D) Change in resistance due to migration at 20 hours in dermal fibroblasts from a 
diabetic donor, shown as bar graphs (left). Line graphs show the time course of the change of 
resistance for all the treatments with 0.4% S4PL concentration (right). *p < 0.05 compared with 
no treatment group and †p < 0.05 compared with the FGF-2 group. 
 
Figure 3. Syndesomes alter endosomal processing of FGF-2. HEK cells were transfected with 
GFP-Rab5, GFP-Rab7 and GFP-Rab11 separately. These cells were treated with AF594 labeled 
FGF-2 and syndesomes. (A) Percentage of Rab5 endosomes that co-localize with labeled FGF-2 
with or without syndesomes. The image panel shows GFP-Rab5, AF594 FGF-2 and merge 
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channels for the two treatments. (B) Percentage of Rab7 endosomes that co-localize with labeled 
FGF-2 with or without syndesomes. The image panel shows GFP-Rab7, AF594 FGF-2 and 
merge channels for the two treatments. (C) Percentage of Rab11 endosomes that co-localize with 
labeled FGF-2 with or without syndesomes. The image panel shows GFP-Rab11, AF594 FGF-2 
and merge channels for the two treatments. (D) Percentage of Rab4 endosomes that co-localize 
with labeled FGF-2 with or without syndesomes. The image panel shows GFP-Rab4, AF594 
FGF-2 and merge channels for the two treatments. (E) Percentage of Rab9 endosomes that co-
localize with labeled FGF-2 with or without syndesomes. The image panel shows GFP-Rab9, 
AF594 FGF-2 and merge channels for the two treatments. *Statistically different from FGF-2 
group at the same time point (p < 0.05; n =10).  
 
Figure 4. Syndesomes enhance cutaneous wound healing in ob/ob mice on high fat diet. (A) 
Custom-made mold for fabricating alginate disks and the alginate disk. (B) Macroscopic images 
of wound closure over 14 days with various treatments. (C) Quantification of the open wound 
area (%) over 14 days using the macroscopic wound images. (D) Immunostaining of the wound 
sections for cytokeratin to visualize the epidermal regrowth following wounding. “W” refers to 
the initial wound and “F” refers to the subcutaneous fat area. The edge of the fat layer marks the 
wound edge. Bar = 250 µm. (E) Quantification of the regrowth of the epidermis beyond the 
wound edge in various treatment groups. (F) Histological sections from the wounds in ob/ob 
mice after 14 days with treatment with syndesomes (S4PL) and FGF-2. The sections were 
stained with Movat’s pentachrome stain. Bar = 1 mm. *Statistically different from all treatment 
groups (p < 0.05; n = 8). 
 
Figure 5. Syndesomes increase perfusion in the developing wound beds. (A) Laser speckle 
contrast image of the dorsal surface of the mice with the four wounds 7 days post surgery and a 
heat map showing relative blood flow. (B) Quantification of blood flow in the wounds at day 7, 
relative to perfusion on the day of surgery. (C) Histological sections of wound bed after 14 days 
after wounding immunostained for an endothelial marker (von Willebrand factor). Bar = 125 µm 
and insets are magnified 1.5 times. (D) Quantification of the number of vessels per field of view 
in the wound bed for different treatment groups. *Statistically different from all other groups (p < 
0.05; n = 8). #Statistically different from the control and S4PL groups (p < 0.05; n = 8).  
Page 29 of 48 
  
 
Figure 6. Syndesomes temporally modulate the macrophage response to wound healing 
phenotype. (A) Histological sections of the wound beds 14 days post-surgery with 
immunostaining for an M1 macrophage marker (CD86). Bar = 125 µm and insets are magnified 
threefold. (B) Quantification of CD86 positive cells within the wound beds. *p < 0.05 versus 
FGF-2 group (n = 8). (C) Histological sections of the wound beds 14 days post-surgery with 
immunostained for an M2 macrophage marker (CD163). Bar = 125 µm and insets are magnified 
threefold. (D) Quantification of the number of CD163 positive cells in the wound beds. *p < 0.05 
versus FGF-2 group (n = 8). (E) Analysis of cells harvested from wounds in ob/ob mice after 2 
or 6 days post surgery using flow cytometry. Cells were stained for macrophage marker (F4/80) 
and compared to the total cells measured in the wound. *p < 0.05 versus all other groups at day 6 
(n = 5). (F) Median intensity of staining for M2 macrophage marker (CD206) in macrophages 
harvested from wounds 2 or 6 days post surgery using flow cytometry. *p < 0.05 versus all other 
groups at day 6 (n = 5). (G) Heat map image of the fold change (compared to control group) in 
the concentration of various cytokines in the wounds 6 days after surgery. (H, I, J) 
Concentrations (pg/ml) of IL-1α, IL-4 and IL-6, respectively, in the wound bed at days 2 and 6 
measured using ELISA normalized to the total protein concentration. *p < 0.05 versus the FGF-2 
group at the same day (n = 5). 
 
Figure 7. Summary diagram of the findings of the study and the enhancing activity of the 
syndesomes.  
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SUPPLEMENTAL FIGURE LEGENDS  
 
Supplemental Figure S1. (A) Silver stained SDS-PAGE gel from the purification of the 
syndecan-4. Numbers at the top of the gel represent fractions isolated from the chromatography 
column. (B) Western blot for syndecan-4 on the pooled and purified protein. The lane labeled 
“S4” was loaded with the purified protein. 
  
Supplemental Figure S2. (A) Transmission electron microscopy on proteoliposomes using thin 
sectioning. The formulations shown relate the protein to lipid ratio in percent (eg. P20:L80 
would be a proteoliposome mixture from 20% protein and 80% lipid solutions with 
concentrations as listed in the Materials and Methods Section). (B) A plot of measured diameters 
for the proteoliposomes. (C) Zeta potential for liposomes and syndecan-4 proteoliposomes after 
syndecan-4 incorporation.  
 
Supplemental Figure S3. Dynamic light scattering analysis of syndecan-4 protein, liposomes, 
syndecan-4 proteoliposomes (S4PL) and S4PL after being released from an alginate gel. The 
S4PLs were released from an alginate gel for one week at 37°C.   
 
Supplemental Figure S4. Quantification of cell invasion in healthy and type 2 diabetic adult 
dermal fibroblasts compared to healthy control group. The cells were treated with FGF-2 and/or 
various concentrations of S4PL. *Statistically different from all treatment groups (p < 0.05; n = 
6).  
 
Supplemental Figure S5. (A) Macroscopic image of the dorsal surface of an ob/ob mouse at day 
14 after wounding and treatment with dressings containing PBS, FGF-2, S4PL or S4PL with 
FGF-2. (B) Quantification of the wound closure (% open) using the macroscopic wound images 
over 2 weeks. *Statistically different from all treatment groups (p < 0.05; n = 8). (C) Histological 
sections from the wounds of mice stained with H&E stain. The wounds were treated with 
combinations of syndesomes (S4PL) and FGF-2. The images are progressively magnified with 
scale bars of length 1 mm, 500 µm and 250 µm. (D) Quantification of the granulation tissue area 
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in the wound bed from the histological H&E images. *Statistically different from all treatment 
groups (p < 0.05; n = 8). 
 
Supplemental Figure S6. Images from the antibody array analysis on the wound bed lysates for 
the cytokines listed in the Supplemental Table S3 for wounds treated with combinations of 
syndesomes (S4PL) and/or FGF-2 in an alginate wound dressing.  
 
Supplemental Figure S7. Cytokine concentrations in wound lysates from wounds at day 6 
following wounding measured through the antibody array. The wounds were treated with 
combinations of syndesomes (S4PL) and FGF-2 in an alginate gel. *p < 0.05 versus FGF-2 group 
(n = 5). The complete data set is shown in the Supplemental Table S3. 
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  Figure 2 
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  Figure 3 
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Figure 5 
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Figure 6 
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Supplemental Figures  
Supplemental Figure S1 




Supplemental Figure S2 
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Supplemental Figure S5 




Supplemental Figure S6 





Supplemental Figure S7 




    
Suppl. Table S1. Patient Sample Data 
Diabetes Status Sex Age 
Normal M 59 
Normal F 49 
Normal M 69 
Normal M 59 
Normal M 62 
Normal F 49 
Normal F 80 
Normal M 69 
Normal F 39 
Diabetic, type II M 53 
Diabetic, type II M 73 
Diabetic, type II F 47 
Diabetic, type II M 80 
Diabetic, type II M 81 
Diabetic, type II M 79 
Diabetic, type II M 53 
Diabetic, type II M 61 
Diabetic, type II M 67 

















Suppl. Table S2. Antibodies used in the studies 
Protein/Label Antibody Company Use 
Syndecan-4 Rabbit polyclonal ABCAM Immunostaining 
Von Willebrand factor Rabbit polyclonal Dako Immunostaining 
Cytokeratin Rabbit polyclonal ABCAM Immunostaining 
CD86 Rabbit polyclonal Bioss USA Immunostaining 
CD163 Rabbit polyclonal Bioss USA Immunostaining 
CD86-Biotin Rat IgG2b BD Biosciences Flow cytometry 
Streptavidin - PerCP N/A BD Biosciences Flow cytometry 
CD206 - FITC Mouse IgG1 BD Biosciences Flow cytometry 
F4/80 – PeCy7 Rat IgG2a eBioscience Flow cytometry 




Suppl. Table S3. Cytokine expression in wound bed six days after wounding 
Cytokine Control FGF-2 S4PL S4PL + FGF-2 
BLC 30.45 + 14.21 39.73 + 11.72 52.59 + 23.71 76.97 + 22.58 
CD 30L 34.20 + 15.18 28.48 + 12.35 43.44 + 26.03 48.01 + 20.39 
Eotaxin 3174.79 + 115.92 1926.48 + 247.99 3128.88 + 270.70 3264.42 + 440.21 
Eotaxin-2  290.04 + 51.21 611.72 + 70.62 787.54 + 134.46 1074.59 + 377.49 
Fas ligand  52.51 + 22.39 59.05 + 16.54 74.70 + 18.41 98.47 + 12.49 
Fractalkine  33.96 + 12.00 48.63 + 12.90 55.37 + 17.29 88.83 + 15.33 
GCSF 67.40 + 36.17 72.63 + 14.13 47.44 + 13.18 117.43 + 44.50 
GM-CSF  52.07 + 18.46 36.09 + 19.77 58.06 + 25.28 50.74 + 27.17 
IFN-gamma  147.03 + 15.63 92.65 + 18.98 170.91 + 36.36 141.94 + 43.20 
IL-1 alpha 750.90 + 188.02 292.27 + 29.96 821.81 + 167.57 609.46 + 128.10 
IL-1 beta 16.88 + 5.67 14.23 + 4.74 30.11 + 12.31 46.69 + 5.63 
IL-2  58.48 + 14.84 55.45 + 25.60 98.20 + 38.12 91.42 + 25.97 
IL-3 63.16 + 24.77 53.64 + 19.96 84.12 + 30.57 72.16 + 27.26 
IL-4 41.83 + 13.93 62.58 + 31.07 75.77 + 41.84 95.00 + 29.23 
IL-6 101.51 + 10.49 91.17 + 28.34 124.57 + 32.61 227.00 + 118.18 
IL-9 131.68 + 20.53 84.39 + 21.09 125.83 + 32.92 128.90 + 28.72 
IL-10 51.86 + 23.56 40.27 + 19.84 69.77 + 25.35 58.31 + 32.66 
IL-12p40/p70 79.00 + 45.43 49.40 + 28.89 91.78 + 36.50 58.16 + 30.83 
IL-12p70 54.16 + 2.88 70.88 + 26.81 91.04 + 36.29 125.74 + 36.55 
IL-13 59.46 + 14.52 66.36 + 16.19 93.87 + 36.79 119.54 + 24.63 
IL-17 120.67 + 24.36 69.19 + 7.12 88.05 + 12.61 72.28 + 11.23 
I-TAC 154.82 + 16.64 134.10 + 16.29 206.93 + 62.15 246.65 + 74.55 
KC 223.54 + 78.72 382.57 + 62.77 231.77 + 33.05 396.89 + 24.38 
Leptin 44.76 + 11.47 48.31 + 10.73 78.93 + 26.50 90.26 + 21.33 
LIX  185.04 + 56.91 132.51 + 17.73 180.95 + 43.34 246.85 + 54.30 
Lymphotactin 166.59 + 23.89 137.37 + 10.06 189.07 + 49.73 262.15 + 49.09 
MCP-1  66.30 + 16.36 65.63 + 32.63 117.64 + 48.68 108.15 + 52.34 
MCSF 113.60 + 15.77 135.65 + 7.20 128.30 + 44.47 223.31 + 49.53 
MIG 87.55 + 22.16 90.69 + 7.06 148.32 + 14.92 131.76 + 9.83 
MIP-1 alpha 31.26 + 6.38 54.07 + 22.59 41.35 + 7.67 93.03 + 27.02 
MIP-1 gamma 24721.6 + 567.8 14590.3 + 2285.6 23424.8 + 2067.4 20532.3 + 936.6 
RANTES 352.05 + 38.72 204.73 + 33.05 505.36 + 115.01 384.12 + 122.85 
SDF-1 64.14 + 12.08 51.24 + 8.66 87.92 + 20.20 96.95 + 13.28 
TCA-3 12.98 + 7.39 33.89 + 11.20 39.26 + 20.85 54.91 + 16.12 
TECK 46.96 + 23.13 66.59 + 23.83 79.41 + 50.32 106.65 + 42.31 
TIMP-1 496.18 + 166.38 698.18 + 205.26 512.35 + 99.29 854.05 + 97.45 
TIMP-2 99.21 + 15.41 78.52 + 17.56 102.48 + 9.80 112.40 + 8.96 
TNF-alpha  47.99 + 25.70 40.59 + 23.75 79.95 + 30.37 59.58 + 32.81 
sTNF RI 7080.18 + 959.66 4372.77 + 437.26 6292.81 + 571.25 5617.42 + 249.09 
sTNF RII 6648.71 + 1311.09 4498.08 + 650.66 6710.83 + 869.92 5853.39 + 861.35 
*Data is shown as densitometry on the array spot (n = 4).  
 
